MediWound Ltd. H.C. Wainwright 28th Annual Global Investment Conference

Okay. You spoke about everything. I have nothing to add.

Hi, thank you for hosting us, and as I said, you summarized quite nicely what we are doing. We have a technology that works. It is validated, published in more than 150 publications. We succeeded in 14 out of 14 clinical trials. We have our first commercial product, which is NexoBrid. It is a drug that removes eschar in severe burns. Our next pipeline product, which is the same technology, it is not only the same technology, it is the same product itself, but with a different concentration, is for a market which is much larger. As for the strategy, I think that it is important to emphasize that we have a company that is not a scientific risk. We are based on something which is approved. We have the first drug that generates revenue, and now we are moving forward to the next challenge, and the exciting milestone is near term.

This is a great question. We have a technology that, as I said, works. When you apply our enzymes on a tissue, it removes the non-viable tissue, the normal tissue, the one that is not protected by melanin, and it removes it. There are a few indications that can be relevant for that. The first one was the most severe one. You want to get rid as soon as possible from the dead tissue. Indeed, you need to change the strategy of how burns are treated in burn centers. It is not easy. It takes a lot of time in order to change the way how a surgeon works in burn centers. There are additional indications. The one that we are speaking about soon is the chronic wounds, that you just shift a current treatment.

It has a lot of advantages, avoid scarring, avoid the pain, very quick, as effective as a knife. You just need to work on the right indications.

I don't think that in MediWound, you need to wait 18 months for catalysts. The main catalyst, by far the most important one, is the phase III VALUE trial that we have. This will determine the real value of the company if it becomes a significant one. As an investor, I will look at the enrollment. I will look at safety. I don't know if you saw the release from today, that the product is actually safe, and no one stops the trial or changes the way we need to handle it. I would watch the top-line data, and after that, everything will speak for itself. What else I would follow is the fact that we are broadening the market or the indication of EscharEx.

We want that when the trial will read out, it will be very clear that we have also indications that are very relevant, such as diabetic foot ulcers and pressure ulcers. All of it is going to initiate soon and be available once we have the venous leg ulcers readout. On top of that, we have the commercial asset, which is NexoBrid, keep on generating revenues. All kind of agreements with governments worldwide. Finishing, at last, the manufacturing facility and having it approved in order to be able to support the global demand. I wouldn't wait 18 months. I think the main catalyst is at the end of the first quarter, and the future of the company will be determined by then.